Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity

To join this study, you need to be an adult, at least 18 years old. You must also be about to start taking brodalumab (SILIQ) for your psoriasis as part of your regular medical care, and you shouldn't have received your first dose yet. It's important that the decision to use brodalumab was made between you and your doctor before you were even asked about this study.

You also need to be able to read and understand information in either English or French, and you should be comfortable using an online platform to complete forms and answer questions. If you have Crohn's disease or are allergic to brodalumab or any of its ingredients, you won't be able to join. Also, if you're taking part in another clinical trial that involves a new treatment, or have done so recently, you wouldn't be able to join this one.

If you decide to take part, you'll first give your verbal permission, and then receive an online informed consent form to read and sign electronically to confirm you understand and agree. After that, the study will simply follow your progress with brodalumab over 12 months. You won't be given any experimental medication; you'll take brodalumab exactly as prescribed by your doctor for your psoriasis.

Throughout the 12 months, you'll be asked to regularly fill out questionnaires online (sometimes called ePROs – electronic Patient Reported Outcomes). These questions will ask about your psoriasis, your quality of life, and how it affects your work. You'll need a computer or mobile device to complete these. The doctors involved will also collect information from your routine clinic visits. You can expect the study to last for about 12 months from the time you enrol.